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Background: Cigarette smoking is a common risk factor for developing nasopharyngeal carcinoma. However, the
relationship between smoking and clinical outcomes remains uncertain.
Methods: The patients who participated in this study were drawn from a randomized clinical trial, for which the
purpose was to compare the efficacy of induction chemotherapy plus concurrent chemoradiotherapy with that of
induction chemotherapy plus radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
The patients who ever smoked were divided into the following categories of cumulative smoking exposure based
on the duration of smoking and the quantity of cigarettes smoked: light, short-term smokers; light, long-term
smokers; heavy, short-term smokers; and heavy, long-term smokers. A log-rank test and Cox models were used to
assess the association between smoking and the clinical outcomes of overall survival (OS), failure-free survival (FFS),
locoregional recurrence failure-free survival (LRFFS) and distant failure-free survival (DFFS).
Results: We found that ever-smokers experienced significantly shorter LRFFS times than never-smokers (5-year
LRFFS rates: 85.8% vs. 88.5%, P = 0.022). The amount of smoking was significantly associated with FFS (P = 0.046)
and LRFFS (P = 0.001) in the different ever-smoker groups. The amount of smoking was associated with LRFFS [P = 0.002,
HR = 2.069 (95% confident interval (CI), 1.298-3.299)] even after a multivariable adjustment.
Conclusions: Smoking increases the risk of locoregional recurrence. Furthermore, the amount of smoking influences the
prognosis of smokers, and these effects are dose-dependent.
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Nasopharyngeal carcinoma (NPC) is rare in most parts of
the world but is endemic in southern China and southern
Asia. There were approximately 84,400 incident cases of
NPC and 51,600 NPC-related deaths in 2008 throughout
the world [1]. A variety of risk factors have been correlated
with NPC, including alcohol, tobacco, Cantonese-style
salted fish, occupational exposures and herbal drugs [2].* Correspondence: maihq@sysucc.org.cn
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unless otherwise stated.Among these, smoking has been definitively associated with
the risk for the onset of NPC because former and current
smokers display increased risks compared to never-
smokers [3]. It was reported that 301 million smokers
lived in China in 2010 [4]. To date, little information
exists regarding cigarette smoking and the progression
and outcome of NPC, which reveals the importance of
analyzing the prognostic role of cigarette smoking among
NPC patients.
We hypothesized that cigarette smoking is associated
with the biological prognosis and clinical outcome for
NPC. To verify our hypothesis, we used the data from a
large, prospective, randomized clinical trial that compared
the efficacy of induction chemotherapy plus concurrent
chemoradiotherapy (IC+CCRT) with that of induction. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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locoregionally advanced nasopharyngeal carcinoma [5,6].
Methods
Ethics statement
The clinical trial and this retrospective study were ap-
proved by the Research Ethics Committee of Sun Yat-sen
University Cancer Center, Guangzhou, PR China. All pa-
tients had signed informed consent forms in the clinical
trial, and informed consent was given by participants for
their clinical records to be used in this study. Patient re-
cords were anonymized and de-identified prior to analysis.
Patient selection
The patients who participated in this study were drawn
from a randomized clinical trial, for which the purpose
was to compare the efficacy of induction chemotherapy
plus concurrent chemoradiotherapy (IC+CCRT) with that
of induction chemotherapy plus radiotherapy (IC+RT) in
patients with locoregionally advanced nasopharyngeal car-
cinoma; the clinical trial was conducted from February
2002 to April 2005 in our institute. All these patients had
been treated with a unified conventional, 2-dimensional
technique in line with the treatment policy for NPC at
Sun Yat-sen University Cancer Center. Every patient had
been given conditional radiotherapy at 2 Gy per fraction
and 5 daily fractions per week, with a total dose of
68-70Gy. In the IC+CCRT group, the patients were treated
with 2 cycles of floxuridine +carboplatin (FuDR, 750 mg/m2,
d1-5; carboplatin, area under the curve, AUC=6). Radiother-
apy had been administered to these patients one week after
completing chemotherapy. Carboplatin (AUC=6) had been
given to the patients in this group on days 7, 28 and 49 while
undergoing treatment with RT. Two cycles of FuDR
d1-d5+carboplatin (FuDR, 750 mg/m2, d1-5; carboplatin,area
under the curve, AUC=6) were administered to the patients
in the IC+RT group. All of these patients had received RT
one week after completing chemotherapy. Only 7 patients
had interruption of RT. The details of the therapeutic
process could be seen in the previous studies regarding the
clinical trial [5,6].
In the present study, the variables that were available for
analysis included a history of ever smoking (ever-smokers or
never-smokers), the amount of smoking presented as ciga-
rettes per day (CPD) (never smoked, ≤9, 10-19, 20-29, ≥30),
the duration of the smoking interval (never smoked, <10,10-
19.9, 20-29.9, 30-39.9, ≥40 yr) and time since the cessation
of smoking (≥10, 5-9.9, ≤4.9 yr). These criteria were chosen
based on previous studies [7-13]. All of the above data
regarding smoking were prospectively collected before
diagnosis. At the time of diagnosis, we divided all the
NPC patients through self-reporting into ever-smokers
and never-smokers, which were defined as having smoked
100 cigarettes or less than 100 cigarettes in the lifetimeaccording to Centers for Disease Control and Prevention
(CDC) of America, respectively [14]. Ever-smokers in-
cluded former smokers and current smokers, who were
defined as having quit smoking for more than 1 year or
who consistently smoked within the last year, respect-
ively. We further categorized the patients who ever
smoked into the following groups of cumulative smok-
ing exposure based on the duration of smoking and
the quantity of cigarettes smoked: light, short-term
smokers (≤19 CPD for ≤19.9 yr); light, long-term smokers
(≤19 CPD for ≥20 yr); heavy, short-term smokers (≥20
CPD for ≤19.9 yr); and heavy, long-term smokers (≥20
CPD for ≥20 yr). Cut-off for cumulative smoking ex-
posure was selected based on the midpoint of the four
categories of duration of smoking and quantity smoked.
Cutoff values of VCA IgA and EA IgA were set at 1:80 for
VCA IgA and 1:10 for EA IgA, which were based on pre-
vious studies [15,16]. Acute mucosal toxicity were evalu-
ated and recorded in accord with Common Terminology
Criteria for Adverse Events (CTCAE) version 2.0.Statistical analysis
All the events were measured from the date of random
assignment, and the statistical tests were performed using
the SPSS17.0 software (SPSS Inc., Chicago, IL). Descriptive
statistics were calculated for patient and disease character-
istics according to smoking. The associations between the
categorical variables were assessed using the ϰ2 test. The
survival rates were calculated using the Kaplan–Meier
method, and the differences between the groups were com-
pared using the log-rank test. Cox regression models were
used to calculate the HRs with the associated 95% CIs for
the associations between clinical outcomes and the follow-
ing multiple smoking parameters: history of ever smoking
(ever-smokers or never-smokers), the amount of smoking
(never smoked, ≤9, 10-19, 20-29, ≥30 yr), the duration of
the smoking interval (never smoked, <10,10-19.9, 20-29.9,
30-39.9, ≥40 yr), the time since smoking cessation (≥10,
5-9.9, ≤4.9) and the cumulative smoking exposure (light,
short-term smokers; light, long-term smokers; heavy,
short-term smokers; heavy, long-term smokers). The Cox
regression models were adjusted for the effects of age,
gender, T stage, N stage and treatment arm. Two-sided
P values less than 0.05 were considered statistically
significant.Results
Baseline characteristics
As previously described by Huang [5,6], no significant
differences were observed in FFS, locoregional control
or distant control between the IC+RT and IC+CCRT
groups. The IC+CCRT regimen did not improve the
overall survival or failure-free survival of patients with
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pared with the IC+RT regimen [5,6].
In the present study, the mean age of all the patients
was 43 yr (range: 18-65 yr). The characteristics of the
study population according to smoking status are de-
scribed in Table 1. Of the 400 patients, 207 (51.7%) were
never-smokers and 193 (48.3%) were ever-smokers. The
ever-smokers included 34 (17.6%) former smokers and
159 (82.4%) current smokers. The numbers of ever-smokersTable 1 Baseline characteristics of 400 patients with




















IC + CCRT 99(51.3) 101(48.8)
IC + RT 94(48.7) 106(51.2)
RT dose(Gy),median(range) 72(68-78) 72(68-78) 0.773
















Abbreviations: IC + CCRT = induction chemotherapy plus concurrent
chemoradiotherapy and IC + RT = induction chemotherapy plus radiotherapy.
RT = radiotherapy. CT = chemotherapy. AMT = Acute mucosal toxicity.in each of the cumulative smoking exposure groups were as
follows: 32 (16.8%) patients were light, short-term smokers;
18 (8.4%) were light, long-term smokers; 57 (29.8%) were
heavy, short-term smokers; and 86 (45.0%) were heavy,
long-term smokers. Age, the tumor size (T1-2, T3-4), the
lymph node status (N0-1, N2-3), the clinical stage, the treat-
ment arm, RT doses, RT interruptions, CT courses, acute
mucosal toxicity(1-2,3-4), VCA-IgA (Positive(≥1:80), Nega-
tive(<1:80)), EA-IgA (Positive(≥1:10), Negative(<1:10)) and
the median follow-up time did not differ between the never-
smokers and ever-smokers, but there was a difference re-
garding gender (P<0.001) (Table 1). Age, the tumor size
(T1-2, T3-4), the lymph node status (N0-1, N2-3), the clin-
ical stage, the treatment arm, RT doses, RT interruptions,
CT courses, acute mucosal toxicity(1-2,3-4), VCA-IgA (Posi-
tive(≥1:80), Negative(<1:80)), EA-IgA (Positive(≥1:10),
Negative(<1:10)) and the median follow-up time were
not different between the 4 cumulative smoking groups,
but there was a difference regarding gender (P=0.005)
(Table 2).
Survival results according to cumulative smoking
exposure and multivariate analysis for different endpoints
The median follow-up time was 80.2 mo (range=40.9-
92.1 mo). During the follow-up, 149 patients (37%) died,
121 patients (30%) had distant metastasis, and 62 (16%)
patients experienced a locoregional recurrence.
For the entire group, the actuarial 5-yr OS, FFS, LRFFS
and DFFS rates were 71.5%, 62.6%, 86.2% and 71.5%, re-
spectively. OS, FFS and DFFS were not associated with
smoking between the ever-smokers and never-smokers.
As shown in Figure 1, the 5-yr LRFFS rates in ever-smokers
and never-smokers were 85.8% and 88.5% (P=0.022), re-
spectively. After adjusting for age, gender, the T stage, the N
stage, the clinical stage and the treatment arm, smoking was
still related to LRFFS [P=0.002, HR=2.223 (95% CI,
1.351-3.658)] (Table 3).
No significant difference in the OS, FFS, LRFFS or
DFFS rates between the former and current smokers
was evident. The 5-yr OS rates in the light, short-term
smokers, the light, long-term smokers, the heavy, short-
term smokers and the heavy, long-term smokers were
62.0%, 77.8%, 74.3% and 63.0%, respectively. No signifi-
cant difference was found among these 4 cumulative
smoking groups in OS, FFS, DFFS or LRFFS. We found
that the amount of smoking was significantly associated
with FFS (P=0.046) and LRFFS (P=0.022) in the ever-
smokers, but this factor was not associated with OS or
DFFS (Figures 2 and 3). The duration of smoking was
not associated with OS, FFS, DFFS or LRFFS. After adjust-
ing for age, gender, the T stage, the N stage, the clinical
stage and the treatment arm, the amount of smoking was
significantly associated with LRFFS [P=0.002, HR=2.233
(95% CI, 1.351-3.658)].
Table 2 Baseline characteristics of 193 ever-smokers with locoregionally advanced nasopharyngeal carcinoma
Light, short-term Light, long-term Heavy, short-term Heavy, long-term P value
32(16.8%) 18(8.4%) 57(29.8%) 86(45.0%)
Age, yr, median 40(20-58) 50(36-60) 39(24-59) 49(10-66) 0.452
Gender 0.005
Female 1(3.1) 1(12.5) 0 0
Male 31(96.9) 17(87.5) 57(100) 86(100)
T stage 0.368
1-2 7(21.9) 1(5.6) 8(14.0) 13(15.1)
3-4 25(78.1) 17(94.4) 49(86.0) 73(84.9)
N stage 0.463
0-1 16(48.5) 6(33.3) 25(43.9) 45(52.3)
2-3 17(51.5) 12(66.7) 32(56.1) 41(47.7)
Clinical stage 0.189
3 15(46.9) 14(75.0) 34(59.6) 43(50.0)
4 17(53.1) 4(25.0) 23(40.4) 43(50.0)
Treatment arm 0.641
IC + CCRT 16(50.0) 11(61.1) 32(56.1) 41(47.7)
IC + RT 16(50.0) 7(38.9) 25(43.9) 45(52.3)
RT dose(Gy),median(range) 72(68-78) 72(68-78) 72(68-78) 72(68-78) 0.118
CT course, median(range) 2(2-5) 32(1-5) 22(1-5) 22(1-5) 0.470
RT interruption
Yes 2(6.2) 0(0) 1(1.8) 1(1.2) 0.337
No 30(93.8) 18(100) 55(98.2) 85(98.8)
AMT 0.731
1-2 30(93.8) 18(100) 52(92.9) 80(93.0)
3-4 2(6.2) 0(0) 4(7.1) 6(7.0)
VCA-IgA 0.330
Positive(≥1:80) 30(93.8) 17(94.4) 47(83.9) 79(91.9)
Negative 2(6.3) 1(5.6) 9(16.1) 7(8.1)
EA-IgA 0.121
Positive(≥1:10) 27(84.4) 17(94.4) 39(69.6) 67(77.9)
Negative 5(15.6) 1(5.6) 17(30.4) 19(22.1)
Median follow-up yr (range) 6.8(0.5-8.7) 6.9(1.1-8.3) 6.5(0.2-8.6) 6.2(0.6-9.0) 0.572
Abbreviations: IC + CCRT = induction chemotherapy plus concurrent chemoradiotherapy and IC + RT = induction chemotherapy plus radiotherapy. AMT = Acute
mucosal toxicity.
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Tobacco use, which is responsible for approximately one-
third of all cancer deaths annually, is the largest prevent-
able cause of cancer and cancer mortality [17]. Nearly half
of our study cases were current or former smokers, which
emphasizes the fact that smoking is significantly associ-
ated with the risk for the onset of NPC. Jia et al. reported
that individuals who reported a high cumulative amount
of smoking had an increased risk of NPC compared with
never-smokers [18]. A number of studies have reported
that smoking is a predictor of unfavorable survival amonghead and neck cancer patients [17,19-22], and most of
these studies have shown that smoking before treatment is
associated with a worse clinical outcome. A multicenter
European study demonstrated that cigarette smoking ad-
versely affects survival, in particular, in cases of a tumor
originating at the endolarynx [20]. A prospective cohort
study indicated that smoking status was the strongest pre-
dictor of survival in both current smokers [hazard ratio
(HR) =2.4; 95% CI, 1.3-4.4] and former smokers (HR =2.0;
95% CI, 1.2-3.5), and the data revealed a significant associ-
ation with poor survival among patients with head and
Figure 1 Comparison among ever-smokers and never-smokers on locoregional recurrence failure free survival of 400 patients with
locoregionally advanced nasopharyngeal carcinoma.
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that, among male NPC patients, smokers have a signifi-
cantly reduced 5-yr overall survival and locoregional re-
currence free survival compared with non-smokers [23].
Ouyang et al. found that the risks of death, progression,
locoregional relapse, and distant metastasis were signifi-
cantly higher for former and current smokers than never
smokers [24]. Both of the two recent researches were
retrospective studies.
The present study utilized data from a randomized clin-
ical trial that included 400 patients with locoregionally ad-
vanced carcinoma. We prospectively collected data of
smoking before diagnosis, so the results of our study
may be more credible than the two retrospective stud-
ies [23,24]. We have found that cigarette smoking is
significantly associated with an increased incidence ofTable 3 Multivariable analysis of LRFFS among all patients
using a Cox regression model
Characteristics HR 95%CI P value
Age 1.002 0.969-1.035 0.924
Gender 0.134 0.016-1.149 0.067
T stage 0.871 0.426-1.781 0.705
N stage 0.915 0.569-1.473 0.715
Clinical stage 1.799 0.705-4.589 0.219
Treatment arm 1.160 0.605-2.224 0.654
Smoking amount 2.223 1.351-3.658 0.002
Abbreviations: HR = hazard ratio; CI = confidence interval.locoregional disease failure. However, we did not find
the relevance between cigarette smoking and OS, FFS
and DFFS in the present study. Because some of the
patients who experienced local regional recurrence could
be cured by salvage therapy. Novel treatment techniques
and strategies-including precision radiotherapy, endo-
scopic surgery, radical neck dissections third-generation
chemotherapy regimens, and targeted therapies and im-
munotherapy have provided hope for patients with recur-
rent nasopharyngeal carcinoma [25,26]. So smoking does
not have an impact on OS. Smoking is a factor for tumor
growth, and cigarette smoke acts as a mutagen and DNA
damaging agent that drives tumor initiation in normal
epithelial cells [27,28]. Cigarettes could cause genetic
mutations and methylation, thereby resulting in the
transformation of epithelial cells in the nasopharynx,
an area in contact with potentially carcinogenic sub-
stances in cigarettes directly through inhalation [29].
So cigarette smoking has impact on local epithelial
cells directly, although not having sufficient power to
significantly influence disease distant metastasis.
Smoking is a factor for tumor growth, and cigarette
smoke acts as a mutagen and DNA damaging agent that
drives tumor initiation in normal epithelial cells [27,28].
Cigarettes could cause genetic mutations and methyla-
tion, thereby resulting in the transformation of epithelial
cells in the nasopharynx, an area in contact with poten-
tially carcinogenic substances in cigarettes directly through
inhalation [29]. DNA mutations can influence local
Figure 2 Comparison among different amount of smoking groups on failure free survival of 400 patients with locoregionally advanced
nasopharyngeal carcinoma.
Figure 3 Comparison among different amount of smoking groups on locoregional recurrence failure free survival of 400 patients with
locoregionally advanced nasopharyngeal carcinoma.
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increase also distant metastasis that is frequently causes of
death. However the present study showed the 5-year
distant failure free survival (DFFS) in ever-smokers and
never-smokers was 70.4% and 70.7%, respectively (P>0.05).
Because the effect of chemotherapy in lowering distant fail-
ure is controversial in head and neck cancer, including
NPC. Adjuvant cisplatin and fluorouracil chemotherapy
did not significantly improve DFFS after concurrent che-
moradiotherapy in locoregionally advanced nasopharyngeal
carcinoma [31,32]. Also there was no difference in DFFS
between those patients treated with induction chemother-
apy followed by chemoradiotherapy and those who re-
ceived chemoradiotherapy alone [33,34]. Although DNA
mutations have impact on resistance to chemotherapy, ac-
tually they have little impact on disease distant metastasis.
In our study, the patients who smoked more cigarettes
per day were significantly associated with FFS and LRFFS.
After adjusting for the T stage, the N stage, the clinical
stage, age and gender, the amount of smoking was still an
independent prognostic factor for LRFFS according to the
Cox regression analysis. It reveals that the more cigarette
smoking, the more risk of locaregional disease recurrence
and disease progression in patients of nasopharyngeal car-
cinoma. This is in accordance with a previous study.
Crosignani et al. reported that heavy tobacco smoking
appeared to worsen the prognoses of male laryngeal
cancer patients in a dose-dependent manner [19]. The
exact explanation of this dose-dependent effect remains
uncertain. It has been hypothesized that the more
cigarette smoking, the more impact on the epithelial
cells of nasopharynx. As a result, the risk of disease
recurrent would be higher in those who smoked more
cigarettes. We did not find any association between
time duration of smoking and prognosis. It means
that the time duration of smoking is not a prognostic
factor for nasopharyngeal carcinoma. The actual mechan-
ism about the relationship of the amount of smoking as
well as time duration and prognosis would be searched by
further molecular study. In the present study, former
smokers did not differ from current smokers regarding
LRFFS; the number of patients who had quit smoking
may have been too small to reveal any differences.
In our study, acute mucosal toxicity was not different
between ever-smokers and never-smokers. The relation-
ship between acute mucosal toxicity and smoking of NPC
patients remains uncertain. The result about acute muco-
sal toxicity is in accordance with several previous studies.
Vatca et al. reported that no-smokers had a significant in-
crease in the risk of developing severe mucositis in
oropharyngeal squamous cell carcinoma [35,36]. Other
studies yet did not find differences between smoking
and mucositis in tumors including head and neck can-
cer [37-39]. Only one study regarding nasopharyngealcarcinoma found that smoking history are high risk
factors of serious mucositis after radiotherapy for 102
NPC patients in 2005 [40]. But there were some limi-
tations to the above study. The enrolled patients were
treated with conventional radiotherapy, using cobalt 60 or
X-ray. And the sample size was too small to provide valu-
able evidence. The association between smoking and acute
mucosal toxicity need to be explored by further large-
scale sample studies.
The exact mechanisms underlying the impact of smoking
on cancer genesis and progression remain elusive. Recent
studies showed that nicotine decreases the effectiveness of
RT and chemoradiotherapy [30,41]. A previous publication
revealed a relationship between smoking status and tumor
oxygen unloading capacity [42]. Tobacco smoking is known
to have immunosuppressive effects on local tissues via
induction of pro-inflammatory cytokines and chemo-
kines and suppression of antigen recognition and re-
sponse. Cigarette smoking affects a wide range of immune
functions impacting innate and adaptive host immunity,
smoking induced changes in antibody production, particu-
larly in response to foreign antigens that impinge on the
respiratory mucosa [43]. Moreover, chronic exposure to
cigarette smoke or nicotine causes T cell unresponsive-
ness, and nicotine-induced immunosuppression may
result from its direct effects on lymphocytes [44,45].
Cigarette smokers exhibit impaired NK cytotoxic activ-
ity, increased pro-inflammatory cytokines production
by peripheral mononuclear cells, and increased T-cell
proliferative response to mitogens [46,47]. Smoking is
a factor for tumor growth, and cigarette smoke acts as
a mutagen and DNA damaging agent that drives tumor
initiation in normal epithelial cells [27,28]. Cigarettes
could cause genetic mutations and methylation, thereby
resulting in the transformation of epithelial cells in the
nasopharynx, an area in contact with potentially carcino-
genic substances in cigarettes directly through inhalation
[29]. Nicotine consistently reduced the cytotoxic effects
of DNA-damaging agents used in treatment, such as
cisplatin and UV and gamma radiation [30]. Besides,
Epstein–Barr virus (EBV) also played a role in the pro-
gression of nasopharyngeal carcinoma. EBV reactiva-
tion in B cells could be triggered by cellular products
of tumor cells [48]. Conversely, EBV might act as a
promoter for tumorigenesis in a feedback loop. EBV
reactivation is associated with the elevations of levels of cy-
tokines and growth factors, ie, interleukin-6, interleukin-
10, transforming growth factor-β1, and vascular endothelial
growth factor, which could contribute to cell proliferation,
immune system perturbation, and angiogenesis [49-52].
Our study has some limitations. First and foremost,
other smoking forms were not recorded, such as hookah
smoking, smoking a pipe, second-hand smoke and so
on. In addition, our data were collected from a single
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sion from our center can be expanded to other regions.
Multicenter clinical trials may be able to verify the value
of pretreatment smoking cessation in locoregional ad-
vanced nasopharyngeal carcinoma patients.
Conclusions
We determined the effects of cigarette smoking on the
clinical outcomes of NPC patients. Smoking leads to an
increased risk of locoregional disease recurrence. Further-
more, the amount of smoking influences the prognosis of
smokers, and patients who smoked more cigarettes per
day have a greater risk of locoregional disease recurrence
than those who smoke fewer cigarettes per day.
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